Navigation Links
Octapharma USA Submits BLA for octaplasLG®, a Therapy Targeting Adverse Transfusion Events
Date:2/27/2012

.octapharma.com/en/about-octapharma/products-therapies/intensive-care-and-emergency-medicine/octaplas-octaplaslg-tolerability-and-safety-in-plasma-transfusion.html">octaplasLG®, coordinating a physician advisory board meeting in late 2011 with leading treatment professionals in transfusion medicine, hematology and surgery.

About the Octapharma Group
Headquartered in Lachen, Switzerland, Octapharma AG is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation for nearly 30 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam® (immune globulin intravenous [human] 5%), is used to treat primary immune deficiencies, and Octapharma's Albumin (human)® is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® (Von Willebrand Factor/Coagulation Factor VIII Complex [human]) received orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for the treatment of certain types of Von Willebrand Disease (VWD). Octapharma employs over 4,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J.  Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit

SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Octapharma USA Appoints Global Biopharmaceutical Executive David E. Holliday as Vice President of Commercial Development
2. Octapharma Announces octagam® 5% Again Available for U.S. Purchase
3. FDA Approves U.S. Market Return for octagam® Following Octapharmas Implementation of Enhanced Safety Measures
4. Octapharma USA to Participate in Important Medical Meetings at AABB, NHF, ASHP and ASH
5. Octapharma Launches Clinical Trial to Evaluate Efficacy & Safety of wilate® In Preventing Surgical Bleeding in Type 3 von Willebrand Disease Patients
6. Octapharma USA Sponsors International Advisory Board for Evaluating Treatment of Patients with von Willebrand Disease
7. Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
8. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
9. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
10. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
11. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 China Biologic Products, Inc. ... fully integrated plasma-based biopharmaceutical company in China ... learned from a public announcement issued by Shanghai RAAS ... listed on Shenzhen Stock Exchange, that on May 21, ... ("Ms. Chan"), one of the shareholders of the Company, ...
(Date:5/24/2013)... , May 24, 2013 In accordance with Rule ... Rule 14e-1 of the United States Exchange Act, Echo Pharma ... offer for Elan Corporation (NYSE: ELN). Background ... Pharma") made an offer for the entire of the issued ... ("Elan") (the "Original Offer").  On 20 May ...
(Date:5/24/2013)... -- The potential of the pulmonary route ... agents has been receiving undeniable attention with the recent ... The crucial formulation considerations for orally inhaled products together ... role in the efficiency of pulmonary delivery, and great ... formulation techniques and devices in recent years. ...
Breaking Medicine Technology:China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2
... Mass. and SYDNEY, April 15, 2011 HeartWare ... HIN), a leading innovator of less invasive, miniaturized ... of advanced heart failure, today announced the presentation ... heart transplantation (BTT) study, ADVANCE, showing 180-day survival, ...
... Nanotechnologies, Inc. ("Shrink") (OTCBB:INKN), an innovative high technology ... Shrink,s Cell Align™ cell culturing and tissue engineering ... substrate has been filed with the US Patent ... a micro-fabricated substrate with non-periodic (or random) linear ...
Cached Medicine Technology:HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 2HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 3HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 4HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 5Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO 2Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO 3
(Date:5/24/2013)... Los Angeles, CA (PRWEB) May 24, 2013 ... “Looking Good on Facebook: Social Media Leads to Spikes in ... indicate that there is a growing prevalence of facial ... utilize social media. These people have become keenly aware of ... profiles on sites such as Facebook, Google and even Skype's ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- The number ... units after spending time in an emergency room ... new research. The study, conducted by researchers ... Health and Health Services in Washington, D.C., found ... room on average before being admitted to the ...
(Date:5/24/2013)... fractional flow reserve (FFR) using pressure wire assessment ... leads to significant changes in the management of ... a study reported at EuroPCR 2013. , The ... strategy at coronary angiography for diagnosis of chest ... assessment of FFR in all the main coronary ...
(Date:5/24/2013)... Ore. A new discovery at Oregon Health & ... body effectively reacts when infected with the highly evasive ... researchers has been utilizing this unique approach to develop ... shown promising results in animal studies. This latest research ... edition of the journal Science . , ...
(Date:5/24/2013)... CBT News.com recently announced the addition of Tom Gonter as ... news organization with 12 years experience in online and social ... that’s so forward-thinking in their approach,” says Gonter. “CBT News ... on the rise.” , Atlanta born and raised, Gonter began ... at Cycle News and Boating World. He made the move ...
Breaking Medicine News(10 mins):Health News:Facebook and Google – Is Social Media Driving Demand for Plastic Surgery? 2Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2Health News:OHSU research highlights promising strategy to help vaccines outsmart HIV 2
... , ... , an Australian start-up, has been selected to showcase its revolutionary service for managing ... ... Global financial innovation conference, Finovate, has selected Controlabill to showcase its revolutionary service for ...
... ... accreditation by COLA, a national healthcare accreditation organization. , ... (PRWEB) March 24, 2010 -- This year, US ... performance in quality patient testing and overall exemplary application of the principles of laboratory ...
... The ... But, what most of us don’t know is that chemotherapy wreaks havoc on our teeth ... with your dental health while undergoing chemotherapy and radiation. , ... (PRWEB) March 24, 2010 -- Steven McConnell - a Marin ...
... , ... will be presenting three sessions in April to increase awareness in the U.S. about the ... can increase early detection and prevention. , ... New York, NY (Vocus) March 24, 2010 -- The Bella Moss Foundation, a ...
... , ... Many of seniors, greatest fears are tied to the loss ... to remain active because of conditions that often accompany aging. But staying ... Paul Hogan. In response to mounting research that underscores the mental and ...
... ... ... -- At just over 18 pounds and with a sound level of only 58 dBA, ... quieter than its battery-operated competitors. Powered by a lithium ion battery with 30 minutes of ...
Cached Medicine News:Health News:Global Financial Innovations Conference Chooses Australian Start Up, Controlabill 2Health News:US Wellness, Inc. Receives National Recognition for Laboratory Excellence 2Health News:Recommended Dental Care for Chemotherapy Patients -- Advice from Steven McConnell, DDS 2Health News:Recommended Dental Care for Chemotherapy Patients -- Advice from Steven McConnell, DDS 3Health News:The Bella Moss Foundation Announces U.S. Tour to Raise Awareness of MRSA in Pets 2Health News:The Bella Moss Foundation Announces U.S. Tour to Raise Awareness of MRSA in Pets 3Health News:Senior Fear Factors: What Aging Americans Fear Most 2Health News:Senior Fear Factors: What Aging Americans Fear Most 3Health News:Advance Introduces the Adgility™ XPB Battery Backpack Vacuum – the Lightest in the Industry, 2
This set offers the full range of Keeler magnifiers and telescopes....
... Featuring up to ... allows examination in the ... sections plus the option ... for corneal transillumination., ,Filters ...
... image guided surgery system offers full-featured ... design and use. It provides unparalleled ... localize critical anatomy and plan optimal ... surgeons an easy-to-use, technologically advanced approach ...
Comes complete with its own case. A unique integrated design with no need for two separate bars., ,Optical surfaces are recessed for optimum protection. Extensive prism power 1,2,3,4,6,8,10,15,20...
Medicine Products: